{
    "clinical_study": {
        "@rank": "87425", 
        "arm_group": {
            "arm_group_label": "Implantation of Neo-kidney Augment", 
            "arm_group_type": "Experimental", 
            "description": "Patients receiving one dose (implant) of NKA into the left kidney"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if selected renal cells, obtained by biopsy from a\n      patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can\n      be safely implanted back into the patient."
        }, 
        "brief_title": "A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus, Type 2", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1 safety and tolerability study to determine if NKA, manufactured from a\n      patient's renal biopsy tissue, can be safely implanted back into the kidney of the patient.\n      Patients must have CKD and Type 2 Diabetes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 2 diabetes mellitus (T2DM).\n\n          -  Patients with CKD defined as glomerular filtration rate (GFR) of 25 - 50\n             mL/min/1.73m2, inclusive, and macroalbuminuria that cannot be explained by an\n             alternative diagnosis.\n\n          -  BMI \u2264 40 at Screening.\n\n          -  Systolic blood pressure between 105 and 140 mmHg (inclusive) and diastolic blood\n             pressure \u2264 90 mmHg.\n\n          -  The patient should have historical data to provide a reasonable estimate of the rate\n             of progression of CKD\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes mellitus (DM).\n\n          -  History of a renal transplant.\n\n          -  HbA1c > 10% at Screening.\n\n          -  Hemoglobin levels < 9 g/dL prior to biopsy or implant.\n\n          -  Known allergy to kanamycin or structurally similar aminoglycoside antibiotics.\n\n          -  Abnormal coagulation status as measured by activated partial prothrombin time,\n             international normalized ratio (INR), and/or platelet count.\n\n          -  Ineligible for a biopsy (e.g., based on size or cortical depth), MRI or renal\n             scintigraphy study (e.g. due to hypersensitivity or allergy) according to standard\n             site practices.\n\n          -  Not a good candidate for laparoscopic surgical procedure (based on the assessment of\n             the surgeon who will be performing the implant).\n\n          -  Clinically significant infection requiring parenteral antibiotics within 6 weeks of\n             biopsy or implantation.\n\n          -  Patients with small kidneys (average size < 9 cm) or only one kidney.  Patients with\n             a rapid decline in renal function over the last 3 months prior to biopsy or acute\n             kidney injury.\n\n          -  Patients with any of the following conditions prior to biopsy: renal tumors,\n             polycystic kidney disease, renal cysts or other anatomic abnormalities that would\n             interfere with the biopsy or implantation procedure (e.g., cysts in the pathway of\n             the injection for implantation), hydronephrosis, skin infection over proposed biopsy\n             sites, or evidence of a urinary tract infection.\n\n          -  Female subjects who are pregnant, lactating (breast feeding) or planning a pregnancy\n             during the course of the study.\n\n          -  History of cancer within the past 3 years (excluding non-melanoma skin cancer and\n             carcinoma in situ of the cervix).\n\n          -  Life expectancy of less than 2 years.\n\n          -  Any contraindication or known anaphylactic or severe systemic reaction to either\n             human blood products or materials of animal (bovine, porcine) origin or anesthetic\n             agents.\n\n          -  Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or\n             Hepatitis C Virus (HCV) assessed.\n\n          -  Subjects with active tuberculosis (TB) requiring treatment in the past 3 years.\n\n          -  Immunocompromised subjects or patients receiving immunosuppressive agents.\n\n          -  Subjects with uncontrolled diabetes, incapacitating cardiac and/or pulmonary\n             disorders.\n\n          -  History of active alcohol and/or drug abuse that in the investigator's assessment\n             would impair the subject's ability to comply with the protocol.\n\n          -  Patients with clinically significant hepatic disease.\n\n          -  Patients with bleeding disorders or abnormal bleeding time that would, in the opinion\n             of the Investigator, interfere with the performance of study procedures; patients\n             taking Coumarins (e.g.,Warfarin) or other anticoagulants (e.g. enoxaparin or direct\n             thrombin inhibitors).\n\n          -  Use of any investigational product within 3 months of the biopsy ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008851", 
            "org_study_id": "TNG-CL011"
        }, 
        "intervention": {
            "arm_group_label": "Implantation of Neo-kidney Augment", 
            "description": "Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient", 
            "intervention_name": "Neo-kidney augment", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic kidney disease", 
            "Type 2 Diabetes", 
            "Neo-kidney augment", 
            "Regenerative medicine"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "UNC Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37235"
                    }, 
                    "name": "Vanderbilt University"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease", 
        "other_outcome": {
            "description": "Exploratory objectives include assessment of renal function over time; e.g., glomerular filtration rate (GFR), serum creatinine, and proteinuria.", 
            "measure": "Changes in renal function over time", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "mcallister@medstudies.com", 
            "last_name": "Eric McAllister, MD"
        }, 
        "overall_official": {
            "affiliation": "Tengion, Inc.", 
            "last_name": "Alice T Robertson, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events related to study procedures or investigational product", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008851"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of renal-specific adverse events", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Tengion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tengion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}